LCTX
Income statement / Annual
Last year (2023), Lineage Cell Therapeutics, Inc.'s total revenue was $8.95 M,
a decrease of 39.16% from the previous year.
In 2023, Lineage Cell Therapeutics, Inc.'s net income was -$21.49 M.
See Lineage Cell Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$8.95 M
|
$14.70 M
|
$3.90 M
|
$773,000.00
|
$1.48 M
|
$1.42 M
|
$1.79 M
|
$2.25 M
|
$2.53 M
|
$1.95 M
|
Cost of Revenue |
$1.36 M |
$728,000.00 |
$1.43 M |
$385,000.00 |
$412,000.00 |
$302,000.00 |
$168,000.00 |
$358,000.00 |
$1.11 M |
$837,052.00 |
Gross Profit |
$7.58 M |
$13.98 M |
$2.47 M |
$388,000.00 |
$1.07 M |
$1.11 M |
$1.62 M |
$1.89 M |
$1.43 M |
$1.11 M |
Gross Profit Ratio |
0.85 |
0.95 |
0.63 |
0.5 |
0.72 |
0.79 |
0.91 |
0.84 |
0.56 |
0.57 |
Research and Development
Expenses |
$15.58 M
|
$13.99 M
|
$33.91 M
|
$12.32 M
|
$17.95 M
|
$20.96 M
|
$24.02 M
|
$36.11 M
|
$42.60 M
|
$37.53 M
|
General & Administrative
Expenses |
$17.30 M
|
$22.51 M
|
$18.21 M
|
$15.57 M
|
$24.03 M
|
$24.73 M
|
$19.92 M
|
$28.43 M
|
$29.13 M
|
$17.56 M
|
Selling & Marketing
Expenses |
-$562,001.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$16.74 M
|
$22.51 M
|
$18.21 M
|
$15.57 M
|
$24.03 M
|
$24.73 M
|
$19.92 M
|
$28.43 M
|
$29.13 M
|
$17.56 M
|
Other Expenses |
-$4,000.00 |
-$2.15 M |
-$445,000.00 |
-$1.05 M |
-$2.04 M |
-$1.32 M |
$1.45 M |
-$403,000.00 |
-$160,000.00 |
-$374,715.00 |
Operating Expenses |
$32.31 M |
$36.50 M |
$51.68 M |
$26.84 M |
$39.94 M |
$42.11 M |
$42.28 M |
$60.86 M |
$67.24 M |
$51.79 M |
Cost And Expenses |
$33.68 M |
$37.22 M |
$53.11 M |
$27.22 M |
$40.35 M |
$42.41 M |
$42.45 M |
$61.22 M |
$68.34 M |
$52.63 M |
Interest Income |
$1.63 M |
$829,000.00 |
$2,000.00 |
$1.04 M |
$1.69 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Interest Expense |
$0.00 |
$5.18 M |
$0.00 |
$0.00 |
$1.69 M |
$10.87 M |
-$17.37 M |
-$77.59 M |
-$18.00 M |
-$6.89 M |
Depreciation &
Amortization |
$692,000.00
|
$727,000.00
|
$887,000.00
|
$2.11 M
|
$3.13 M
|
$3.27 M
|
$3.30 M
|
$4.76 M
|
$6.33 M
|
$8.41 M
|
EBITDA |
-$24.04 M
|
-$19.82 M
|
-$52.79 M
|
-$25.01 M
|
-$54.30 M
|
-$32.19 M
|
-$53.97 M
|
-$142.38 M
|
-$63.17 M
|
-$50.67 M
|
EBITDA Ratio |
-2.69 |
-1.35 |
-13.55 |
-32.36 |
-36.74 |
-22.73 |
-30.12 |
-63.22 |
-24.93 |
-26.03 |
Operating Income Ratio
|
-2.77
|
-1.53
|
-12.63
|
-34.21
|
-26.3
|
-29.52
|
-21.71
|
-26.18
|
-25.97
|
-26.04
|
Total Other
Income/Expenses Net |
$1.45 M
|
-$3.29 M
|
$5.94 M
|
$4.52 M
|
$19.64 M
|
-$6.85 M
|
$18.06 M
|
$78.34 M
|
$3.50 M
|
-$383,641.00
|
Income Before Tax |
-$23.28 M |
-$25.81 M |
-$43.27 M |
-$21.92 M |
-$19.23 M |
-$47.13 M |
-$23.29 M |
$18.62 M |
-$62.65 M |
-$51.15 M |
Income Before Tax Ratio
|
-2.6
|
-1.76
|
-11.11
|
-28.36
|
-13.01
|
-33.28
|
-13
|
8.27
|
-24.72
|
-26.28
|
Income Tax Expense |
-$1.80 M |
$541,000.00 |
-$4.71 M |
-$1.24 M |
-$7.41 M |
-$346,000.00 |
-$37.29 M |
-$175.95 M |
-$4.52 M |
-$7.38 M |
Net Income |
-$21.49 M |
-$26.35 M |
-$38.56 M |
-$20.69 M |
-$11.83 M |
-$45.99 M |
-$19.98 M |
$33.57 M |
-$46.99 M |
-$36.41 M |
Net Income Ratio |
-2.4 |
-1.79 |
-9.9 |
-26.76 |
-8 |
-32.48 |
-11.15 |
14.91 |
-18.54 |
-18.71 |
EPS |
-0.12 |
-0.16 |
-0.23 |
-0.14 |
-0.0813 |
-0.36 |
-0.17 |
0.35 |
-0.59 |
-0.55 |
EPS Diluted |
-0.12 |
-0.16 |
-0.23 |
-0.14 |
-0.0813 |
-0.36 |
-0.17 |
0.34 |
-0.59 |
-0.55 |
Weighted Average Shares
Out |
$172.66 M
|
$169.79 M
|
$164.50 M
|
$150.04 M
|
$145.53 M
|
$126.90 M
|
$114.48 M
|
$97.32 M
|
$79.71 M
|
$66.36 M
|
Weighted Average Shares
Out Diluted |
$172.66 M
|
$169.79 M
|
$164.50 M
|
$150.04 M
|
$145.53 M
|
$126.90 M
|
$114.48 M
|
$99.55 M
|
$79.71 M
|
$66.47 M
|
Link |
|
|
|
|
|
|
|
|
|
|